Compare Pfizer Inc (PFE) vs Visa Inc (V) Price & Performance

Pfizer (PFE) trades at $24.83, up 0.32% today, with a neutral technical signal and bearish moving averages. The company reported revenue of $62.58B in 2025, with a net income margin of 11.83%, and has beaten EPS estimates for the last three quarters. Recent news highlights pipeline developments in oncology and obesity, with a consensus analyst price target of $28.25.

PFE offers a stable dividend and trades below analyst targets, but faces headwinds from patent expirations and volatile cash flows. The stock presents value with a P/E of 19.04, though growth depends on successful drug launches and navigating post-COVID revenue normalization.

Visa (V) trades at $353.42, down 1.98% on the day, but maintains a bullish technical trend with strong analyst support. The company reported robust earnings beats in recent quarters, with Q1 2026 EPS of $3.31 exceeding the $3.10 estimate. Revenue growth remains steady, reaching $40 billion in 2025, while profitability metrics like a 51.68% net income margin highlight operational efficiency. Recent news highlights Visa's push into AI-driven commerce and stablecoin partnerships, positioning it for future payment innovations.

The outlook for Visa is positive, driven by consistent earnings outperformance, high analyst buy ratings (85%), and a consensus price target of $396.70 implying ~12% upside. Key risks include competitive pressures from fintech and regulatory scrutiny, but the company's strong cash flow and market dominance provide a solid foundation for long-term growth.